Clinical characteristics, susceptibility profiles, and treatment of nocardiosis: a multicenter retrospective study in 2015-2021

• DOI: 10.1016/j.ijid.2023.02.023
• Publication Date: 2023-03-04T01:33:42Z
• Authors: Jing Yang; Hong-tao Ren; Jie Wang; Ai-ying Dong; Yu-lan Chen; Di-xia Hu; Hao Wang; Hong-meng Ji; Hai-nan Wen; Ying Chen; Dong-yan Shi
• Keywords: Linezolid; Amikacin; Broth microdilution; Trimethoprim; Sulfamethoxazole

This study aimed to investigate the microbiological characteristics, antimicrobial resistance profiles, antibiotic choice, and outcomes of Nocardia infection in various centers over a 7-year period (from 2015 2021).We retrospectively analyzed medical records all hospitalized patients diagnosed with between 2021. The isolates were identified species level through sequencing 16S ribosomal RNA or secA1 ropB genes. susceptibility profiles determined using broth microdilution method.Of 130 nocardiosis cases, 99 (76.2%) established as pulmonary infection, which most common underlying disease was chronic lung (40.4%, 40/99), including bronchiectasis, obstructive disease, bronchitis. Among isolates, 12 identified, being cyriacigeorgica (37.7%) farcinica (20.8%). All strains susceptible linezolid amikacin, rate trimethoprim-sulfamethoxazole (TMP-SMX) 97.7%. Of patients, 86 (66.2%) received TMP-SMX monotherapy multidrug regimen. Furthermore, 92.3% who treated achieved clinical improvement.TMP-SMX treatment choice for nocardiosis, other combination drugs therapy yielded even better results.